Loading organizations...
§ Private Profile · 21 LGA, Alderley Park, Macclesfield, Cheshire, UK
QV Bioelectronics is a technology company.
QV Bioelectronics develops implantable electric field therapy treatments designed to enhance outcomes for patients with aggressive brain tumours. Their primary innovation is GRACE, an implantable device that delivers continuous electric fields directly to the tumour site. This approach targets highly malignant cancers, aiming to provide a localized and sustained therapeutic effect that conventional treatments often struggle to achieve in complex brain environments. The company focuses on the technical precision required for effective long-term implantation and consistent energy delivery.
The company was co-founded in 2018 by Dr. Christopher Bullock, a biomedical engineer, and Dr. Richard Fu, an NHS neurosurgeon. Their collaboration arose from a shared understanding of the significant unmet medical need in treating aggressive brain cancers. Dr. Bullock’s expertise in device engineering combined with Dr. Fu’s clinical insights into neurosurgery formed the foundational knowledge base for developing a novel, direct intervention method for these challenging pathologies.
QV Bioelectronics targets patients diagnosed with aggressive brain tumours, notably Glioblastoma, a condition with historically poor prognoses. The company's long-term vision centers on transforming the treatment landscape for these patients, aiming to extend survival and significantly improve their quality of life. By focusing on an innovative implantable therapy, QV Bioelectronics seeks to establish a new standard of care in neuro-oncology, offering renewed hope for individuals facing critical diagnoses.
QV Bioelectronics has raised $3.2M across 4 funding rounds.
QV Bioelectronics has raised $3.2M in total across 4 funding rounds.
QV Bioelectronics has raised $3.2M in total across 4 funding rounds.
QV Bioelectronics's investors include Stanley Fink, Johnathan Matlock, Curious Capital, Draper Associates, Elbow Beach Capital, SOSV, Catapult Ventures, Duncan Johnson, Vijay Curthan, Dr. Deepak Kotak MD.
QV Bioelectronics is a UK-based medical device startup developing the GRACE implant, an innovative bioelectronic device that delivers continuous electric field therapy (EFT) directly to glioblastoma (GBM) tumor sites post-surgery.[1][2][4] This addresses the aggressive nature of GBM—the most common primary brain cancer in adults with <5% five-year survival rates and only six FDA-approved therapies—by targeting recurrence at resection margins where up to 90% of regrowth occurs, potentially extending patient longevity and quality of life compared to existing EFT devices generating over $0.5 billion in revenue.[1][2][4] The company serves the healthcare sector, focusing on neuro-oncology, and is raising Series A funding after de-risking its technology through large animal and in-vitro studies confirming safety; it has secured £2 million in venture capital and plans expansion to a $30 billion market across related indications.[1][4]
QV Bioelectronics, incorporated on October 7, 2018, as Honeycomb Biotechnology Ltd. (renamed September 4, 2019), emerged from the collaboration of a biomedical engineer and neurosurgeon who identified the dire unmet need in GBM treatment amid stagnant innovation.[1][2][3] Co-founders Dr. Chris Bullock (CEO, PhD MEng AMIMechE) and Dr. Richard Fu (Clinical Director, MB ChB MRes MRCS PhD) combined expertise in medical engineering, oncology, and neurosurgery to conceive the GRACE implant concept.[2] Early traction includes preclinical validation of efficacy and safety in large animal studies over three months, patent filings in brain tumor, cancer treatments, and electrotherapy, plus £2 million in funding and selection for the Texas Medical Center’s Innovation Factory accelerator.[1][4]
QV Bioelectronics rides the wave of bioelectronics and tumor-treating fields (TTFields), a growing modality shifting cancer care from systemic drugs to precise, localized therapies amid GBM's therapeutic stagnation (just 6 FDA approvals vs. 61 for breast cancer).[1][2] Timing aligns with rising demand for recurrence-preventing implants post-surgery, fueled by preclinical successes and a $30+ billion market; market forces like VC interest (£2M raised) and accelerators like Texas Medical Center enable US expansion for UK innovators.[1][4] It influences the ecosystem by validating implantable EFT, potentially catalyzing interdisciplinary medtech (neurosurgery + engineering) and drawing investment to hard-to-treat "cold" tumors, challenging incumbents in a space ripe for paradigm shifts.[1][2]
QV Bioelectronics is primed for first-in-human trials post-Series A, with expanded preclinical work on GRACE's safety/efficacy and device finalization, targeting clinical entry in several years.[1][4] Trends like AI-optimized field therapies, combo implants with immunotherapy, and global GBM awareness will accelerate adoption, evolving its role from GBM pioneer to multi-indication platform leader in a $30B+ market.[1] As bioelectronics matures, QV could redefine post-surgical oncology, delivering the longer, higher-quality lives promised from its origins in unmet neurosurgical need.[2]
QV Bioelectronics has raised $3.2M across 4 funding rounds. Most recently, it raised $2.0M Seed in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2023 | $2M Seed | Stanley Fink, Johnathan Matlock | Curious Capital, Draper Associates, Elbow Beach Capital, SOSV, Catapult Ventures, Duncan Johnson | Announced |
| Jun 1, 2021 | $1M Seed | — | Curious Capital, Draper Associates, SOSV, Vijay Curthan, DR. Deepak Kotak MD | Announced |
| Jul 1, 2020 | $100K Seed | — | Curious Capital, Draper Associates, SOSV | Announced |
| Oct 1, 2018 | $66K Seed | — | Curious Capital, Draper Associates, SOSV | Announced |